Metabolic and endocrine effects of valproic acid chronic treatment

Vincenzo Belcastro; Claudia D'Egidio; Pasquale Striano; Alberto Verrotti

doi:10.1016/j.eplepsyres.2013.08.016

Metabolic and endocrine effects of valproic acid chronic treatment

Vincenzo Belcastro, Claudia D'Egidio, Pasquale Striano, Alberto Verrotti

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

Treatment of epileptic patients with valproic acid (VPA) may be associated with substantial weight changes that may increase morbidity and impair adherence to the treatment regimen. VPA-induced weight gain seems to be associated with many metabolic disturbances; the most frequent are hyperinsulinemia and insulin resistance, hyperleptinemia and leptin resistance. Patients who gain weight during VPA therapy can develop dyslipidemia and metabolic syndrome that are associated with long-term vascular complications such as hypertension and atherosclerosis. Moreover, an elevation in the levels of uric acid and homocysteine, together with oxidative stress, may contribute to atherosclerotic risk in patients under long-term therapy with VPA.The aim of this review is to discuss the metabolic and endocrine effects of VPA chronic treatment in patients with epilepsy.

Original language	English
Pages (from-to)	1-8
Number of pages	8
Journal	Epilepsy Research
Volume	107
Issue number	1-2
DOIs	https://doi.org/10.1016/j.eplepsyres.2013.08.016
Publication status	Published - Nov 2013

Keywords

Atherosclerosis
Epileptic syndromes
Metabolic syndrome
Valproic acid

ASJC Scopus subject areas

Clinical Neurology
Neurology

Access to Document

10.1016/j.eplepsyres.2013.08.016

Cite this

@article{60cef775aeeb4c33aa0615d84785384f,

title = "Metabolic and endocrine effects of valproic acid chronic treatment",

abstract = "Treatment of epileptic patients with valproic acid (VPA) may be associated with substantial weight changes that may increase morbidity and impair adherence to the treatment regimen. VPA-induced weight gain seems to be associated with many metabolic disturbances; the most frequent are hyperinsulinemia and insulin resistance, hyperleptinemia and leptin resistance. Patients who gain weight during VPA therapy can develop dyslipidemia and metabolic syndrome that are associated with long-term vascular complications such as hypertension and atherosclerosis. Moreover, an elevation in the levels of uric acid and homocysteine, together with oxidative stress, may contribute to atherosclerotic risk in patients under long-term therapy with VPA.The aim of this review is to discuss the metabolic and endocrine effects of VPA chronic treatment in patients with epilepsy.",

keywords = "Atherosclerosis, Epileptic syndromes, Metabolic syndrome, Valproic acid",

author = "Vincenzo Belcastro and Claudia D'Egidio and Pasquale Striano and Alberto Verrotti",

year = "2013",

month = nov,

doi = "10.1016/j.eplepsyres.2013.08.016",

language = "English",

volume = "107",

pages = "1--8",

journal = "Epilepsy Research",

issn = "0920-1211",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Metabolic and endocrine effects of valproic acid chronic treatment

AU - Belcastro, Vincenzo

AU - D'Egidio, Claudia

AU - Striano, Pasquale

AU - Verrotti, Alberto

PY - 2013/11

Y1 - 2013/11

N2 - Treatment of epileptic patients with valproic acid (VPA) may be associated with substantial weight changes that may increase morbidity and impair adherence to the treatment regimen. VPA-induced weight gain seems to be associated with many metabolic disturbances; the most frequent are hyperinsulinemia and insulin resistance, hyperleptinemia and leptin resistance. Patients who gain weight during VPA therapy can develop dyslipidemia and metabolic syndrome that are associated with long-term vascular complications such as hypertension and atherosclerosis. Moreover, an elevation in the levels of uric acid and homocysteine, together with oxidative stress, may contribute to atherosclerotic risk in patients under long-term therapy with VPA.The aim of this review is to discuss the metabolic and endocrine effects of VPA chronic treatment in patients with epilepsy.

AB - Treatment of epileptic patients with valproic acid (VPA) may be associated with substantial weight changes that may increase morbidity and impair adherence to the treatment regimen. VPA-induced weight gain seems to be associated with many metabolic disturbances; the most frequent are hyperinsulinemia and insulin resistance, hyperleptinemia and leptin resistance. Patients who gain weight during VPA therapy can develop dyslipidemia and metabolic syndrome that are associated with long-term vascular complications such as hypertension and atherosclerosis. Moreover, an elevation in the levels of uric acid and homocysteine, together with oxidative stress, may contribute to atherosclerotic risk in patients under long-term therapy with VPA.The aim of this review is to discuss the metabolic and endocrine effects of VPA chronic treatment in patients with epilepsy.

KW - Atherosclerosis

KW - Epileptic syndromes

KW - Metabolic syndrome

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=84886949545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886949545&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2013.08.016

DO - 10.1016/j.eplepsyres.2013.08.016

M3 - Article

C2 - 24076030

AN - SCOPUS:84886949545

SN - 0920-1211

VL - 107

SP - 1

EP - 8

JO - Epilepsy Research

JF - Epilepsy Research

IS - 1-2

ER -

Metabolic and endocrine effects of valproic acid chronic treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this